The Effects of Ramipril in Individuals at Risk for Alzheimer’s Disease: Results of a Pilot Clinical Trial

Research shows that certain antihypertensives taken during midlife confer Alzheimer’s disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including CSF amyloid...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Wharton, Whitney, Stein, James H., Korcarz, Claudia, Sachs, Jane, Olson, Sandra R., Zetterberg, Henrik, Dowling, Maritza, Ye, Shuyun, Gleason, Carey E., Underbakke, Gail, Jacobson, Laura E., Johnson, Sterling C., Sager, Mark A., Asthana, Sanjay, Carlsson, Cynthia M.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2012
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3593582/
https://ncbi.nlm.nih.gov/pubmed/22776970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-2012-120763
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة